In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Allergan

This article was originally published in The Rose Sheet

Executive Summary

Allergan: Merger talks with Pharmacia & Upjohn have been discontinued, the Irvine, Calif.-based eye and skin care treatment manufacturer said in a May 13 statement responding to media speculation of a merger. According to the company, the two firms had discussed "a possible stock-for-stock merger with pooling of interest accounting treatment." Allergan recently augmented its skin care business with the purchase of ethical skin care marketer Herald Pharmacal in August ("The Rose Sheet" Aug. 7, p. 7) The buy helped boost the firm's skin care revenues 84% to $13.8 mil. Allergan's prescription skin care offerings include Azelex topical acne cream. The firm also is awaiting U.S. marketing approval for Zorac retinoid tazarotene gel to treat psoriasis and acne...



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts